WallStreetZenWallStreetZen

NASDAQ: BIOL
Biolase Inc Stock

Open Broker Account
$0.77+0.01 (+1.32%)
Updated Dec 8, 2022
BIOL Price
$0.77
Fair Value Price
$2.07
Market Cap
$5.47M
52 Week Low
$0.75
52 Week High
$13.83
P/E
-0.21x
P/B
0.39x
P/S
0.4x
PEG
N/A
Dividend Yield
N/A
Revenue
$46.82M
Earnings
-$24.05M
Gross Margin
36.8%
Operating Margin
-47.36%
Profit Margin
-51.8%
Debt to Equity
2.09
Operating Cash Flow
-$24M
Beta
1.06
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

BIOL Overview

BIOLASE, Inc., together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, such as cosmetic, restorative, and complex surgical applications. The company offers Waterlase all-tissue dental laser systems for cutting soft and hard tissues; diode soft-tissue laser systems for soft tissue, pain therapy, teeth whitening, and cosmetic procedures; and Epic Hygiene laser to manage non-surgical periodontitis and enhance clinical production. It also manufactures and sells consumable products and accessories for its laser systems, as well as markets flexible fibers and hand pieces, and teeth whitening gel kits. The company sells its products through its field sales force and distributor network. The company was formerly known as BIOLASE Technology, Inc. and changed its name to BIOLASE, Inc. in 2012. BIOLASE, Inc. was founded in 1984 and is headquartered in Foothill Ranch, California.

Zen Score

Industry Average (32)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how BIOL scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

BIOL ($0.77) is undervalued by 63.09% relative to our estimate of its Fair Value price of $2.07 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
BIOL ($0.77) is significantly undervalued by 63.09% relative to our estimate of its Fair Value price of $2.07 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
BIOL is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more BIOL due diligence checks available for Premium users.

Be the first to know about important BIOL news, forecast changes, insider trades & much more!

BIOL News

Valuation

BIOL fair value

Fair Value of BIOL stock based on Discounted Cash Flow (DCF)
Price
$0.77
Fair Value
$2.07
Undervalued by
62.85%
BIOL ($0.77) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
BIOL ($0.77) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
BIOL is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

BIOL price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-0.21x
Industry
63.09x
Market
21.39x

BIOL price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
0.39x
Industry
3.8x
BIOL is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

BIOL's financial health

Profit margin

Revenue
$12.0M
Net Income
-$8.4M
Profit Margin
-69.8%
BIOL's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
BIOL's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$42.9M
Liabilities
$29.0M
Debt to equity
2.09
BIOL's short-term assets ($33.88M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BIOL's short-term assets ($33.88M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BIOL's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
BIOL's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$6.5M
Investing
-$2.7M
Financing
-$214.0k
BIOL's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

BIOL vs Medical Device Stocks

TickerMarket Cap1d %P/EP/B
BIOL$5.47M+0.66%-0.21x0.39x
SINT$5.40M-2.80%-0.26x0.57x
INVO$5.60M+10.84%-0.72x4.35x
THMO$5.06M+4.76%-0.16x0.99x
INBS$5.87M+2.89%-0.59x1.13x

Biolase Stock FAQ

What is Biolase's quote symbol?

NASDAQ: BIOL) Biolase trades on the NASDAQ under the ticker symbol BIOL. Biolase stock quotes can also be displayed as NASDAQ: BIOL.

If you're new to stock investing, here's how to buy Biolase stock.

What is the 52 week high and low for Biolase (NASDAQ: BIOL)?

(NASDAQ: BIOL) Biolase's 52-week high was $13.83, and its 52-week low was $0.75. It is currently -94.47% from its 52-week high and 2% from its 52-week low.

How much is Biolase stock worth today?

(NASDAQ: BIOL) Biolase currently has 7,145,529 outstanding shares. With Biolase stock trading at $0.77 per share, the total value of Biolase stock (market capitalization) is $5.47M.

Biolase stock was originally listed at a price of $380.50 in Dec 31, 1997. If you had invested in Biolase stock at $380.50, your return over the last 24 years would have been -99.8%, for an annualized return of -22.8% (not including any dividends or dividend reinvestments).

How much is Biolase's stock price per share?

(NASDAQ: BIOL) Biolase stock price per share is $0.77 today (as of Dec 8, 2022).

What is Biolase's Market Cap?

(NASDAQ: BIOL) Biolase's market cap is $5.47M, as of Dec 10, 2022.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Biolase's market cap is calculated by multiplying BIOL's current stock price of $0.77 by BIOL's total outstanding shares of 7,145,529.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.